December 24, 2013 | The Israeli Office of the Chief Scientist (OCS) has granted biomed company Cell Cure Neurosciences (a subsidiary of Bio Time) NIS 6.1 million. Cell Cure will use the funds to develop its OpRegen product, a cell-based treatment for age-related macular degeneration.
Related posts
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Electronic Tampon Eliminates Yeast Infections
February 01, 2023
Humans Beat AI At Guessing People’s Ages
February 01, 2023
$10M For Cyber Company That Protects Small Businesses
January 31, 2023
Facebook comments